N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.644 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 644-644 ◽

Author(s):

D. L. Graham ◽

D. W. Hillman ◽

T. J. Hobday ◽

S. R. Rousey ◽

S. G. Nair ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

406 POSTER Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MBC) patients: preliminary results from a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80704-9 ◽

2005 ◽

Vol 3 (2) ◽

pp. 113-114 ◽

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Sunitinib Malate ◽

Safety And Efficacy ◽

Download Full-text

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

SpringerPlus ◽

10.1186/2193-1801-3-108 ◽

2014 ◽

Vol 3 (1) ◽

Author(s):

Helen Kent Chew ◽

Lee Schwartzberg ◽

Suprith Badarinath ◽

Peter Rubin ◽

Grace Shumaker ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e11097 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e11097-e11097 ◽

Author(s):

W. Janni ◽

T. Sarosiek ◽

C. A. Papadimitriou ◽

J. V. Álvarez Gallego ◽

M. Caruso ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

10.1158/0008-5472.sabcs12-p5-18-21 ◽

2012 ◽

Author(s):

W Janni ◽

T Sarosiek ◽

J Pikiel ◽

B Karaszewska ◽

E Staroslawska ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-ot1-02-09 ◽

2011 ◽

Author(s):

W Janni ◽

J Pikiel ◽

T Sarosiek ◽

B Karaszewska ◽

CA Papadimitriou ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Trial ◽

Phase Ii ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801)

10.1158/0008-5472.sabcs13-p4-12-26 ◽

2013 ◽

Author(s):

H Gomez ◽

S Neciosup ◽

C Tosello ◽

M Mano ◽

J Bines ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Randomized Study ◽

Metastatic Breast ◽

Second Line ◽

Her2 Positive ◽

Second Line Therapy ◽

Download Full-text

Faculty of 1000 evaluation for Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718021759.793480257 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Progesterone Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

230 A Phase II Study of Pegylated Liposomal Doxorubicin Combined with Cyclophosphamide / 5-fluorouracil as Second Line Chemotherapy in Patients with Metastatic Breast Cancer Who Failed Previous Taxane-based Treatment

European Journal of Cancer ◽

10.1016/s0959-8049(12)70298-8 ◽

2012 ◽

Vol 48 ◽

pp. S109-S110

Author(s):

H.K. Chang ◽

Y.C. Lin ◽

K.M. Rau ◽

Y.Y. Chen ◽

K.D. Lee ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Metastatic Breast ◽

Pegylated Liposomal Doxorubicin ◽

Second Line ◽

Second Line Chemotherapy ◽

Line Chemotherapy

Download Full-text

Docetaxel more active than paclitaxel as second-line therapy for metastatic breast cancer

The Women s Oncology Review ◽

10.1080/14733400600615717 ◽

2006 ◽

Vol 6 (1) ◽

pp. 99-100

Author(s):

Aileen L. Chen ◽

Anna Pavlick

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Second Line ◽

Second Line Therapy ◽

Download Full-text

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

10.1158/1538-7445.sabcs18-pd1-10 ◽

2019 ◽

Author(s):

WR Parulekar ◽

AA Joy ◽

K Gelmon ◽

M Mates ◽

C Desbiens ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text